- Home
- PVLA vs TERN Comparison
PVLA vs TERN Comparison
Compare PVLA & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- TERN
- Stock Information
- Founded
- PVLA 2015
- TERN 2017
- Country
- PVLA United States
- TERN United States
- Employees
- PVLA N/A
- TERN N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- TERN Health Care
- Exchange
- PVLA Nasdaq
- TERN Nasdaq
- Market Cap
- PVLA 253.2M
- TERN 263.8M
- IPO Year
- PVLA N/A
- TERN 2021
- Fundamental
- Price
- PVLA $24.45
- TERN $3.12
- Analyst Decision
- PVLA Strong Buy
- TERN Buy
- Analyst Count
- PVLA 7
- TERN 5
- Target Price
- PVLA $46.29
- TERN $15.63
- AVG Volume (30 Days)
- PVLA 52.4K
- TERN 738.7K
- Earning Date
- PVLA 05-15-2025
- TERN 05-08-2025
- Dividend Yield
- PVLA N/A
- TERN N/A
- EPS Growth
- PVLA N/A
- TERN N/A
- EPS
- PVLA N/A
- TERN N/A
- Revenue
- PVLA N/A
- TERN N/A
- Revenue This Year
- PVLA N/A
- TERN N/A
- Revenue Next Year
- PVLA N/A
- TERN N/A
- P/E Ratio
- PVLA N/A
- TERN N/A
- Revenue Growth
- PVLA N/A
- TERN N/A
- 52 Week Low
- PVLA $11.17
- TERN $1.87
- 52 Week High
- PVLA $29.27
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- TERN 55.15
- Support Level
- PVLA N/A
- TERN $3.01
- Resistance Level
- PVLA N/A
- TERN $3.17
- Average True Range (ATR)
- PVLA 0.00
- TERN 0.18
- MACD
- PVLA 0.00
- TERN 0.01
- Stochastic Oscillator
- PVLA 0.00
- TERN 75.00
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.